BioCentury | May 28, 2020
Distillery Therapeutics

microRNA cluster identified as targets for ischemic stroke

...DISEASE CATEGORY: Neurology INDICATION: Stroke Targeting the miR-15a/miR-16-1 cluster to enhance blood-brain barrier function could treat...
...an endothelial cell surface protein involved in maintaining paracellular barriers and regulating permeability. TARGET/MARKER/PATHWAY: MicroRNA-15a (miR-15a...
...Ke-Jie Yin, University of Pittsburgh School of Medicine, Pittsburgh, Pa. email: yink2@upmc.edu Claire Quang University of Pittsburgh MicroRNA-15a (miR-15a) MicroRNA-16-1...
BioCentury | Aug 13, 2015
Tools & Techniques

Helping Beethoven hear

...the ear August 2013 Hearing loss Lilach Friedman, Tel Aviv University MicroRNA-15a-1 (miR-15a-1); microRNA-18a (miR-18a) miR-15a-1...
BioCentury | Jul 14, 2014
Company News

Santaris, Servier, miRagen deal

The partners extended by two years to October 2016 a 2011 deal to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen’s preclinical programs targeting microRNA-208 ( miR-208 ) and miR-15/195 , plus an undisclosed...
BioCentury | Jun 3, 2013
Company News

miRagen, Santaris, Servier deal

Servier exercised its right to add a third target to a 2011 deal with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. Servier's target selection triggered the first undisclosed milestone payment to miRagen....
BioCentury | Nov 7, 2011
Strategy

Servicing CV

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs. Last month, Servier agreed to...
BioCentury | Oct 24, 2011
Company News

miRagen, Santaris, Servier deal

Servier partnered with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 ( miR-208 ) and miR-15/195, as well as a cardiovascular microRNA modulator yet to be identified....
BioCentury | Oct 19, 2011
Top Story

Servier, miRagen in cardiovascular deal

Servier (Neuilly-sur-Seine, France) partnered with miRagen Therapeutics Inc. (Boulder, Colo.) to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 (miR-208) and miR-15/195, as well as a cardiovascular...
BioCentury | Aug 19, 2010
Distillery Therapeutics

Indication: Cancer

...lymphoblastic leukemia (ALL) IL-23; microRNA-15a (miR-15a) In vitro and mouse studies suggest that IL-23 and miR-15a...
...help treat pediatric ALL. In ALL patient samples and human ALL cell lines, IL-23 upregulated miR-15a...
...than no treatment. In mouse models of pediatric ALL, human IL-23 or forced overexpression of miR-15a...
BioCentury | May 13, 2010
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Stroke MicroRNA-15a (miR-15a); peroxisome proliferation-activated...
...protect against stroke-associated brain damage. In nutrient-deprived mouse cerebral vascular endothelial cells, PPARd overexpression reduced miR-15a-dependent...
...mouse model of stroke, a PPARd agonist significantly reduced infarct size and ischemia-induced upregulation of miR-15a...
BioCentury | Apr 30, 2009
Cover Story

miRNAs sounding better

...and found distinct patterns of expression for multiple miRNA genes in the inner ear, including miR-15a...
Items per page:
1 - 10 of 12